Spotlight On…

DCTD Scientific Advances
This page provides a collection of selected DCTD scientific advances. More…

Approved Oncology Drugs Now Available from DCTD in Plated Sets
More than 50 oncology drugs approved by the Food and Drug Administration are now available from DCTD in plated sets for drug discovery efforts. Researchers may use the sets for many potential purposes, including comparing their compounds with approved oncology drugs and performing drug combination studies. More…

Aminoflavone Prodrug (NSC 710464)
The parent aminoflavone (NSC 686288) showed good differential activity in the NCI 60-cell line screen and marked effects in renal xenografts. More…

Batracylin (NSC 320846)
Batracylin reached Stage 3 of the NCI pipeline, but was dropped in 1989 because of concern about the interspecies differences in toxicity and potential for variable oral absorption. More…

Halichondrin B analog (NSC 707389)
Work done on synthesizing halicondrin B (NSC 609395) showed that only a portion of the molecule was needed for potent biological activity. More…

SAHA (NSC 701852)
SAHA is a potent histone deactylase (HDAC) inhibitor with excellent oral bioavailability. More…

Coordinating Center for Clinical Trials (CCCT)
An NCI office that seeks to enhance the best of all the components of the NCI-supported clinical trials system… More…

Clinical and Translational Advisory Committee (CTAC)
An external NCI committee that shall provide advice to NCI on the NCI-supported national clinical trials and translational research enterprises… More…

Clinical and Translational Research Operations Committee (CTROC)
This committee is designed to coordinate clinical trials and translational programs across the institute and to make recommendations to improve cost-effectiveness and reduce duplication and overlap among NCI components. CTROC will also evaluate new Requests for Applications and Program Announcements in these research areas prior to review by the NCI Executive Committee.

Clinical Trials Working Group (CTWG)
The Clinical Trials Working Group (CTWG), which made 22 recommendations to the National Cancer Advisory Board in 2005 to revamp the NCI's cancer clinical trials system, spawned a new NCI organizational structure designed to oversee the institute's entire clinical trials enterprise. More…

NCI’s Clinical Trials Cooperative Groups National Meeting Report - Summer 2009